Insulin glargine safety clarified by latest evidence

“Patients with diabetes taking insulin glargine (Lantus, Sanofi) do not need to change their insulin therapy,” the ADS statement reads,

“Patients with diabetes can be initiated on glargine therapy without concern that insulin glargine will increase the risk of developing a malignancy.”

The announcement followed studies including the Northern European Study of Insulin and Cancer involving nearly 450,000 patients with diabetes.

Around 17,500 new cases of cancer were examined over 3.1 years of